Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Current Leases (2023 - 2026)

MBX Biosciences has reported Current Leases over the past 4 years, most recently at $178000.0 for Q1 2026.

  • Quarterly results put Current Leases at $178000.0 for Q1 2026, up 36.92% from a year ago — trailing twelve months through Mar 2026 was $178000.0 (up 36.92% YoY), and the annual figure for FY2025 was $172000.0, up 0.58%.
  • Current Leases reached $178000.0 in Q1 2026 per MBX's latest filing, up from $172000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $178000.0 in Q1 2026 and bottomed at $130000.0 in Q1 2025.
  • Median Current Leases over the past 4 years was $160000.0 (2024), compared with a mean of $157750.0.
  • The largest annual shift saw Current Leases dropped 7.23% in 2025 before it skyrocketed 36.92% in 2026.
  • Over 4 years, Current Leases stood at $153000.0 in 2023, then increased by 11.76% to $171000.0 in 2024, then increased by 0.58% to $172000.0 in 2025, then rose by 3.49% to $178000.0 in 2026.
  • Business Quant data shows Current Leases for MBX at $178000.0 in Q1 2026, $172000.0 in Q4 2025, and $154000.0 in Q3 2025.